Health CarePharmaceuticals & Biotechnology
  • Price (HUF)8,670.00
  • Today's Change130.00 / 1.52%
  • Shares traded136.41k
  • 1 Year change+28.06%
  • Beta0.5544
Data delayed at least 15 minutes, as of Oct 20 2021 16:05 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Forecasts data is unavailable for this security.

Consensus recommendation

  • 15-Oct-20
  • 15-Jul-21
  • 19-Aug-21
  • 16-Sep-21
  • 14-Oct-21
Select bar for recommendation details.

Share price forecast

The 8 analysts offering 12 month price targets for Richter Gedeon Vegyeszeti Gyar Nyrt have a median target of 9,836.00, with a high estimate of 11,000.00 and a low estimate of 5,788.00. The median estimate represents a 13.45% increase from the last price of 8,670.00.


In 2020, Richter Gedeon Vegyeszeti Gyar Nyrt reported a dividend of 225.32 HUF, which represents a significant increase over last year. The 3 analysts covering the company expect dividends of 216.04 HUF for the upcoming fiscal year, a decrease of 4.12%.
Div growth (TTM)257.30%
More ▼

Earnings history & estimates

Richter Gedeon Vegyeszeti Gyar Nyrt reported annual 2020 earnings of 563.00 per share on Feb 25, 2021.
Average growth rate+16.62%
More ▼

Revenue history & estimates

Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. had 2nd quarter 2021 revenues of 155.91bn. This bettered the 141.40bn estimate of the one analyst covering the company. This was 10.24% above the prior year's 2nd quarter results.
Average growth rate+4.76%
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. had revenues for the full year 2020 of 566.78bn. This was 11.62% above the prior year's results.
Average growth rate+9.97%
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.